Syncom Formulations (India) Ltd's Q4FY25 Quarter Results
- 20 May 2025
Result Summary
- Syncom Formulations (India) Ltd reported a 41.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 14.6%.
- Its expenses for the quarter were down by 40.8% QoQ and up 17.7% YoY.
- The net profit decreased 43.1% QoQ and decreased 12.6% YoY.
- The earnings per share (EPS) of Syncom Formulations (India) Ltd stood at 0.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 77.67 | 131.57 | 67.75 | -41.0% | 14.6% |
Total Expenses | 67.65 | 114.31 | 57.48 | -40.8% | 17.7% |
Profit Before Tax | 10.03 | 17.26 | 10.28 | -41.9% | -2.4% |
Tax | 2.63 | 4.26 | 1.81 | -38.3% | 45.3% |
Profit After Tax | 7.40 | 13.00 | 8.47 | -43.1% | -12.6% |
Earnings Per Share | 0.10 | 0.10 | 0.10 | 0.0% | 0.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Syncom Formulations (India) Ltd is a company operating in the pharmaceutical industry, primarily involved in the manufacturing and distribution of pharmaceutical formulations. The company is known for producing a wide range of products including tablets, capsules, syrups, ointments, and injectables. As a participant in the healthcare sector, Syncom Formulations focuses on both domestic and international markets, aiming to deliver quality healthcare products. As of the latest known developments, there are no major changes or significant events reported for the company. Further specific information about recent corporate developments or strategic initiatives is not available within the given data.
Revenue
In the fourth quarter of FY25, Syncom Formulations reported a total income of ₹77.67 crores, which marks a decrease from the previous quarter (Q3FY25) where the total income was ₹131.57 crores, reflecting a quarter-over-quarter (QoQ) decline of 41.0%. However, compared to the same quarter of the previous fiscal year (Q4FY24), the total income shows a year-over-year (YoY) increase of 14.6%, up from ₹67.75 crores. This indicates variability in revenue generation across quarters, with a notable drop from the previous quarter but an overall growth compared to the previous year’s corresponding quarter.
Profitability
The company recorded a profit before tax of ₹10.03 crores in Q4FY25, down from ₹17.26 crores in the previous quarter, marking a 41.9% QoQ decrease. When compared to Q4FY24, there is a slight decline of 2.4% from ₹10.28 crores. The tax expense for Q4FY25 was ₹2.63 crores, which is less than the ₹4.26 crores recorded in Q3FY25 but higher than the ₹1.81 crores in Q4FY24, showing a 45.3% YoY increase. The profit after tax for Q4FY25 amounted to ₹7.40 crores, decreasing by 43.1% from the previous quarter’s ₹13.00 crores and by 12.6% from the previous year’s corresponding quarter, which was ₹8.47 crores. Earnings per Share (EPS) remained stable at ₹0.10 across all compared periods.
Operating Metrics
The total expenses for Syncom Formulations in Q4FY25 were ₹67.65 crores, which is a significant decrease of 40.8% from ₹114.31 crores in the previous quarter. Compared to the expenses of ₹57.48 crores in Q4FY24, there is a YoY increase of 17.7%. This reflects changes in the company's cost structure and operational spending across quarters and years. The financial data highlights the adjustments in operating expenses relative to income, which have impacted the profit margins. The consistent EPS over the quarters and the year suggests stability in shareholder returns despite fluctuations in net income figures.